Multiple Sclerosis Research

The mission of the Program in Multiple Sclerosis is to provide the best possible treatment for individuals and their family members suffering from multiple sclerosis (MS) and to educate the community and community based physicians in the recognition and care of patients with MS. We also strive to further knowledge in MS and its treatment through basic and clinical research.

Current Faculty Members Involved in Research:

Emily Pharr, MD


2013-Present:  ASSESS-A study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg with glatiramer acetate 20 mg in patients with relapsing-remitting MS,  Sponsor: Novartis Pharmaceuticals Corporation

2013-Present:  CONCERTO-A study to evaluate the efficacy, safety and tolerability of 2 doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in patients with relapsing-remitting MS,  Sponsor: Teva Pharmaceutical Industries Limited

Contact Information: Janet Hutchens, BS, CCRC,, (336) 716-1715


Last Updated: 10-21-2015
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.